{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:16:30Z","timestamp":1787760990944,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Forensic Science International"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.forsciint.2012.12.020","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T15:17:43Z","timestamp":1358435863000},"page":"e26-e31","source":"Crossref","is-referenced-by-count":38,"title":["A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine"],"prefix":"10.1016","volume":"226","author":[{"given":"J.","family":"Jornil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rosendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ahlner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Zackrisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.W.T.","family":"Boel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12024-010-9188-3","article-title":"Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects","volume":"7","author":"Pilgrim","year":"2011","journal-title":"Forensic Sci. Med. Pathol."},{"issue":"1\u20133","key":"10.1016\/j.forsciint.2012.12.020_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.forsciint.2010.09.011","article-title":"Pharmacogenetics in medico-legal context","volume":"203","author":"Sajantila","year":"2010","journal-title":"Forensic Sci. Int."},{"issue":"1\u20133","key":"10.1016\/j.forsciint.2012.12.020_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.forsciint.2010.07.011","article-title":"Pharmacogenetics and forensic toxicology","volume":"203","author":"Musshoff","year":"2010","journal-title":"Forensic Sci. Int."},{"issue":"24","key":"10.1016\/j.forsciint.2012.12.020_bib0020","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1016\/0006-2952(86)90769-0","article-title":"Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivative","volume":"35","author":"Muth","year":"1986","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/qjmed\/hcg062","article-title":"Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants","volume":"96","author":"Whyte","year":"2003","journal-title":"QJM \u2013 Int. J. Med."},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1192\/bjp.bp.109.070219","article-title":"Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose","volume":"196","author":"Hawton","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ddr.430230210","article-title":"Biochemical, neurophysiological, and behavioral-effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine","volume":"23","author":"Muth","year":"1991","journal-title":"Drug Dev. Res."},{"issue":"7","key":"10.1016\/j.forsciint.2012.12.020_bib0040","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jat\/31.5.254","article-title":"Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels","volume":"31","author":"Reis","year":"2007","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.forsciint.2012.12.020_bib0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00414-010-0461-5","article-title":"Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions","volume":"125","author":"Launiainen","year":"2011","journal-title":"Int. J. Legal Med."},{"issue":"3","key":"10.1016\/j.forsciint.2012.12.020_bib0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/j.1552-4604.1998.tb04423.x","article-title":"Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects","volume":"38","author":"Patat","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.forsciint.2012.12.020_bib0060","unstructured":"Wyeth, Effexor XR Safety Information. Retrieved from FDA website April 2012, http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/."},{"issue":"4","key":"10.1016\/j.forsciint.2012.12.020_bib0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","article-title":"Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting","volume":"24","author":"Reis","year":"2002","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0070","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants","volume":"20","author":"Fogelman","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.forsciint.2012.12.020_bib0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine","volume":"33","author":"McAlpine","year":"2011","journal-title":"Ther. Drug Monit."},{"issue":"5\u20136","key":"10.1016\/j.forsciint.2012.12.020_bib0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00228-003-0627-x","article-title":"Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine","volume":"59","author":"Lindh","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.forsciint.2012.12.020_bib0085","first-page":"435","article-title":"Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans","volume":"9","author":"Lessard","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"7","key":"10.1016\/j.forsciint.2012.12.020_bib0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1358\/dot.2008.44.7.1227147","article-title":"Desvenlafaxine succinate for major depressive disorder","volume":"44","author":"Sproule","year":"2008","journal-title":"Drugs Today"},{"key":"10.1016\/j.forsciint.2012.12.020_bib0095","unstructured":"Wyeth, Pristiq Prescribing Information 2011. Retrieved from FDA website April 2012, http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.forsciint.2012.12.020_bib0110","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P4502C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.forsciint.2012.12.020_bib0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"Shams","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.forsciint.2012.12.020_bib0125","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","article-title":"Physiological approach to hepatic drug clearance","volume":"18","author":"Wilkinson","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.forsciint.2012.12.020_bib0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00498250600683197","article-title":"Prediction of in vivo drug clearance from in vitro data. I. Impact of inter-individual variability","volume":"36","author":"Howgate","year":"2006","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.forsciint.2012.12.020_bib0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab. Pharmacok."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp (R) population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","article-title":"Simulation and prediction of in vivo drug metabolism in human populations from in vitro data","volume":"6","author":"Rostami-Hodjegan","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.forsciint.2012.12.020_bib0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/clpt.2009.216","article-title":"High frequency of occurrence of CYP2D6 gene duplication\/multiduplication indicating ultrarapid metabolism among suicide cases","volume":"88","author":"Zackrisson","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.forsciint.2012.12.020_bib0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/154065802761001301","article-title":"Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing (TM) technology","volume":"1","author":"Eriksson","year":"2002","journal-title":"Assay Drug Dev. Technol."},{"issue":"1","key":"10.1016\/j.forsciint.2012.12.020_bib0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.forsciint.2012.12.020_bib0170","series-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2011"},{"issue":"1","key":"10.1016\/j.forsciint.2012.12.020_bib0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"1\u20133","key":"10.1016\/j.forsciint.2012.12.020_bib0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.forsciint.2011.07.034","article-title":"Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood","volume":"214","author":"Kingback","year":"2012","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/j.forsciint.2012.12.020_bib0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejps.2011.08.003","article-title":"Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator","volume":"44","author":"Jornil","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3\u20134","key":"10.1016\/j.forsciint.2012.12.020_bib0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","article-title":"In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug\u2013drug interactions","volume":"21","author":"Hasselstroem","year":"2006","journal-title":"Drug Metab. Drug Interact."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0195","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","article-title":"Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients","volume":"33","author":"Bakken","year":"2011","journal-title":"Ther. Drug Monit."},{"issue":"10","key":"10.1016\/j.forsciint.2012.12.020_bib0200","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200410000-00005","article-title":"Quetiapine serum concentrations in psychiatric patients \u2013 the influence of comedication","volume":"26","author":"Hasselstrom","year":"2004","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.forsciint.2012.12.020_bib0210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00228-010-0948-5","article-title":"Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients","volume":"67","author":"Andreassen","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.forsciint.2012.12.020_bib0220","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","article-title":"Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite","volume":"32","author":"Klamerus","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.forsciint.2012.12.020_bib0225","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/j.1875-9114.1996.tb03009.x","article-title":"Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics","volume":"16","author":"Klamerus","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0230","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","article-title":"Venlafaxine serum levels and CYP2D6 genotype","volume":"22","author":"Veefkind","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.forsciint.2012.12.020_bib0235","series-title":"Transporters: Importance in Drug Absorption, Distribution, and Removal, in Enzyme- and Transporter-based Drug\u2013drug Interactions","first-page":"27","author":"Russel","year":"2010"},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","article-title":"Venlafaxine oxidation in vitro is catalysed by CYP2D6","volume":"41","author":"Otton","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.forsciint.2012.12.020_bib0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/clpt.2009.102","article-title":"A holy grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient","volume":"86","author":"Benet","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.forsciint.2012.12.020_bib0250","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4172\/jbb.1000076","article-title":"Metabolism studies of desvenlafaxine","volume":"3","author":"DeMaio","year":"2011","journal-title":"J. Bioequiv. Availab."}],"container-title":["Forensic Science International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073812005713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073812005713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T20:37:50Z","timestamp":1714855070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0379073812005713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":50,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0379073812005713"],"URL":"https:\/\/doi.org\/10.1016\/j.forsciint.2012.12.020","relation":{},"ISSN":["0379-0738"],"issn-type":[{"value":"0379-0738","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}